Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences

Pharma Outsourcing igång på Stockholm Waterfront

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Anna Törner: You won’t find this many Concorde projects anywhere else

"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Vi lyfter kromatografisk peptidrening med en ny och innovativ metod

Hög renhetsgrad är avgörande på en konkurrensutsatt marknad. Här följer ett exempel.

Norway finds its path in life science

The life science sector in Norway is on the rise.

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

Björn Arvidsson: Let's build on the positive momentum

Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Science Sweden´s Editor-in-Chief, in an editorial.

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

New diagnostic test soon ready for the market

"Imponerande kraftsamling gav vaccin"

Det rekordsnabba framtagandet av nya vaccin under pandemin visar vad läkemedelsindustrin – och mänskligheten – kan åstadkomma när pressen är tillräckligt stor.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct site in the gastrontestinal tract are two of them.

Bakom de gröna ambitionerna

Många läkemedelsföretag inkluderar i dag ett miljötänk i tillverkningen av läkemedel. Men få är villiga att redovisa faktiska siffror i Life Science Swedens enkätundersökning. (Uppdaterad)

Inga spår av coronavirus när Londons tunnelbana undersöktes

En nyligen genomförd stickprovsundersökning i Londons tunnelbana visade inga spår av sars-cov-2.

Marie Gårdmark: Do EMA and FDA talk to each other?

Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.

Swedish Healthtech Company 1928 Pushing Forward

The full service analytics platform is expanding the business.

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Pilots want to live too